GT BIOPHARMA, INC. Cash and Restricted Cash
GT BIOPHARMA, INC. (GTBP) had Cash and Restricted Cash of $5.05 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-14
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $5.05M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $9.02M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $6.91M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2.62M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $5.05M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $9.02M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $6.91M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $2.62M 10-Q/A · filed 2026-03-06 |
| 2025-06-30 | $5.32M 10-Q · filed 2026-08-14 |
| 2025-03-31 | $2.46M 10-Q · filed 2026-05-15 |
| 2024-12-31 | $4.04M 10-Q · filed 2026-08-14 |
| 2024-09-30 | $6.51M 10-Q/A · filed 2026-03-06 |
| 2024-06-30 | $9.25M 10-Q/A · filed 2026-03-06 |
| 2024-03-31 | $1.95M 10-Q · filed 2025-05-15 |
| 2023-12-31 | $1.08M 10-Q/A · filed 2026-03-06 |
| 2023-09-30 | $2.65M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $2.77M 10-Q · filed 2024-08-14 |
| 2023-03-31 | $2.04M 10-Q · filed 2024-05-15 |
| 2022-12-31 | $5.67M 10-K · filed 2025-02-21 |
| 2022-09-30 | $2.46M 10-Q · filed 2023-11-01 |
| 2022-06-30 | $5.36M 10-Q · filed 2023-08-07 |
| 2022-03-31 | $7.29M 10-Q · filed 2023-05-15 |
| 2021-12-31 | $8.97M 10-K · filed 2024-03-26 |
| 2021-09-30 | $9.68M 10-Q · filed 2022-10-31 |
| 2021-06-30 | $39.51M 10-Q · filed 2022-08-15 |
| 2021-03-31 | $27.55M 10-Q · filed 2022-05-16 |
| 2020-12-31 | $5.30M 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |